195 related articles for article (PubMed ID: 30227885)
21. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
22. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
23. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
Anecchino C; Fanizza C; Marino V; Romero M;
Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
[TBL] [Abstract][Full Text] [Related]
24. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
27. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
[TBL] [Abstract][Full Text] [Related]
28. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
[TBL] [Abstract][Full Text] [Related]
29. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
30. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
31. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
32. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
33. Changes of Metabolic Biomarker Levels upon One-Year Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis: Associations with Vascular Pathophysiology.
Czókolyová M; Pusztai A; Végh E; Horváth Á; Szentpéteri A; Hamar A; Szamosi S; Hodosi K; Domján A; Szántó S; Kerekes G; Seres I; Harangi M; Paragh G; Szekanecz É; Szekanecz Z; Szűcs G
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680168
[TBL] [Abstract][Full Text] [Related]
34. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
35. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
[TBL] [Abstract][Full Text] [Related]
36. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
37. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
[TBL] [Abstract][Full Text] [Related]
38. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
[TBL] [Abstract][Full Text] [Related]
39. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy.
Straub RH; Härle P; Atzeni F; Weidler C; Cutolo M; Sarzi-Puttini P
J Rheumatol; 2005 Jul; 32(7):1253-8. PubMed ID: 15996060
[TBL] [Abstract][Full Text] [Related]
40. Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy.
Erer B; Yilmaz G; Yilmaz FM; Koklu S
Rheumatol Int; 2009 Apr; 29(6):651-4. PubMed ID: 18953538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
